Great-Martyrs Theodore Recruit and General

38 Followers

Sts. Theodore’s Mission statement: "Enlightening those in darkness" Our Lord and Savior Jesus Christ taught us that we are called to be a light to the world. Also by walking in the light of Christ we naturally reaffirm the true Orthodox philotimo (meaning the Holy Spirit guiding a community in its beliefs and aspirations through the contemplation of the Holy Trinity) amongst our brothers and sisters in the Orthodox Church. LINKS: Sts. Theodore ststheodore.org Eastern American Diocese eadiocese.org Holy Trinity Monastery jordanville.org Orthodox Life orthodoxlife.org Orthodox Wisdom youtube.com/@OrthodoxWisdom

The Frontline Dispatchers: Bringing You The Latest News

1 Follower

TheReporters1 is a news channel dedicated to providing in-depth coverage of local and global events, news, and stories that matter to our viewers. Our team of reporters, journalist and news analyst work tirelessly to bring to you the lastest news, breaking stories and exclusive interviews with the key players in the world of politics, business, sports, and more. We strive to provide accurate and unbaised reporting, with a focus on quality journalism that informs, educates and empowers our viewers. From livebreaking news to documentaries and special reports, "TheReporters1" is your go-to source for all things news and current events.

Canadian phase 2 clinical trial, recruiting patients.

0 Followers

C Difficile is a gram positive spore forming bacteria, which can cause severe gut infection. It infects and kills 500,000 and 30,000 North Americans respectively every year. Standard of care treatment is Vancomycin antibiotic, which is effective in 60 to 70% of cases. When unsuccessful, the infection can recur and likeliness of recurrence increases after every treatment failure. Its treatment is considered an unmet medical need by the FDA and as such new treatments showing positive potential are typically fast tracked. ImmuniMed Inc, a Canadian clinical stage Biopharmaceutical company is presently in phase 2 clinical trial of its oral dose antibody treatment and recruiting patients. If you are a Canadian resident, over the age of 18 and have tested positive for c Difficile, please contact us to participate in this trial. John Hare John@immunimed.com 204-955-8495